Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
0.910
+0.458 (101.33%)
At close: Dec 20, 2024, 4:00 PM
0.700
-0.210 (-23.08%)
After-hours: Dec 20, 2024, 7:59 PM EST

Company Description

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.

The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.

Helius Medical Technologies, Inc. was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

Helius Medical Technologies, Inc.
Helius Medical Technologies logo
Country United States
Founded 2014
Industry Medical Devices
Sector Healthcare
Employees 22
CEO Dane Andreeff

Contact Details

Address:
642 Newtown Yardley Road, Suite 100
Newtown, Pennsylvania 18940
United States
Phone 215 944 6100
Website heliusmedical.com

Stock Details

Ticker Symbol HSDT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001610853
CUSIP Number 42328V504
ISIN Number US42328V8019
Employer ID 36-4787690
SIC Code 3845

Key Executives

Name Position
Dane Carl Andreeff President, Chief Executive Officer and Director
Jeffrey S. Mathiesen CPA Chief Financial Officer, Treasurer, Secretary and Director
Dr. Antonella Favit-Van Pelt M.D., Ph.D. Chief Medical Officer
Lawrence Picciano Senior Vice President of Engineering, Quality and Regulatory Affairs

Latest SEC Filings

Date Type Title
Nov 18, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 12, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Aug 9, 2024 8-K Current Report
Jul 24, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 28, 2024 8-K Current Report
Jun 20, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 3, 2024 8-K Current Report